LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

• Status: Not yet recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Leidos Life Sciences
• Collaborator: United States Department of Defense
• Treatments: Celecoxib; Famotidine

Criteria

• For eligibility criteria specific to the protocol, see:

• Addendum #1 (LDOS-21-001-01) or

• Addendum #2 (LDOS-21-001-02)